Johannes Kuchta
Research Subjects
Research Interests
Johannes Kuchta has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
A. Koulousakis
Cologne University
3 shared publicationsA. Bayarassou
Universidad de Colonia, Colonia, Alemania
2 shared publicationsV. Sturm
Cologne University
2 shared publicationsAthanasios Kolousakis
Universidad de Colonia, Colonia, Alemania
1 shared publicationC. Wedekind
1 shared publicationDerald E. Brackmann
1 shared publication
Latest Publications
- Open Access
- 1 November 2009
- Published by Fundacion Cenit in NeuroTarget
- Vol. 4 (3) , 8-15
Opioides por vía intratecal para el tratamiento de los síndromes dolorosos refractarios
For more than 20 years intrathecal opioid application with implantable pumps is an option for selected patients with malignant as well as non-malignant pain. In general, most types of pain should be treatable by opioid medication. However, the associated systemic side-effects such as nausea, vomiting, constipation or the risk of depression of the central nervous system hinder the application of oral or intravenous opioid therapy as a sole, widely applicable treatment. Causes of non-malignant pain that may represent an indication for intrathecal drug-delivery systems include: failed back syndrome, neuropathic pain, axial spinal pain, complex regional pain syndrome, diffuse pain, brachial plexitis, central pain, failed spinal cord stimulation (SCS) therapy, arachnoiditis, poststroke pain, spinal cord injury pain and peripheral neuropathy. Due to the proximity to the receptor sites, the therapeutic effect of intrathecal drug application lasts longer and the rate of systemic side effects is reduced. Before definitive pump implantation, the therapeutic effect of intrathecal opioid therapy is tested with an external pump. If there is no clear and satisfactory effect in this trial application, pump implantation is not indicated. In our patients, with a follow-up exceeding 3 years, the reduction of non-malignant pain (assessed with the Visual Analogue Scale, VAS) was good or excellent (pain decrease >50%) in 71.3% of the patients, fair (VAS 5-6) in 19.8% and poor (VAS 7-10) in 8.9%. After 3 years of continuous treatment, we observed catheter-related technical problems (catheter dislocation, obstruction, kinking, disconnection or rupture) in 17 of 165 patients. Pump malfunctions were very rare (8 of 165 cases) and limited to older pump types. Reversible, specific drug-related side effects of long-term therapy with intrathecal pumps developed in 32 of the 165 patients. In our series, the mean serum/cerebrospinal fluid (CSF) concentration ratio for morphine was 1/3000, which explains the low rate of systemic side effects. Local diffusion difficulties in CSF cause an uneven distribution of morphine in CSF. Therefore the clinical effect is markedly influenced by the position of the catheter tip, a fact that should be kept in mind during catheter implantation. Intrathecal drug application is cost effective and can significantly improve the quality of life in selected patients. An intensive training in this method and awareness of its specific complications is necessary for everyone to participate in the consulting and implanting team. Pumps for chronic intrathecal opioid application should only be implanted in specialized centers. Durante más de veinte años, la aplicación de la terapia con opioides intratecales y con bombas implantables es una opción recurrente para los pacientes seleccionados que presentan dolor maligno o dolor no maligno. Por lo general, la mayor parte de los tipos existentes de dolor deberán ser tratados mediante el uso de medicamentos que contengan opioides. De todos modos, los efectos colaterales adversos sistémicos asociados tales como la náusea, la constipación, el vómito y los riesgos de supresión del sistema nervioso central obstaculizan la aplicación de la terapia intravenosa u oral con opioides como un tratamiento único y de amplia aplicación. Las causas del dolor maligno que pueden representar una indicación de los sistemas intratecales del suministro de drogas incluyen: el dolor neuropático, el síndrome de la cirugía fallida de la espalda, el dolor axial de la columna vertebral, el síndrome de dolor regional complejo, el dolor difuso, la plexitis braquial, el dolor central, la terapia de estimulación fallida de la columna vertebral, la aracnoiditis, el dolor post-stroke, el dolor causado por heridas o lesiones en la columna vertebral y la neuropatía periferal. Debido a la proximidad existente a los sitios receptores, el efecto terapéutico de la aplicación intratecal de las drogas dura más tiempo mientras que el tipo de efectos colaterales adversos sistémicos se reduce. Previamente a realizar el implante definitivo de la bomba, el efecto terapéutico de la terapia con opioides intratecales se prueba con una bomba externa. Si el efecto en esta aplicación de prueba no es ni claro ni satisfactorio, entonces no se indica el implante de la bomba. En nuestros pacientes, mediante un seguimiento que superó los tres años, fue buena la reducción del dolor no maligno (asesorada mediante la aplicación de la Escala Análoga Visual, EAV), fue excelente la reducción del dolor (disminución del dolor del 50%) en el 71, 3 % de los pacientes, fue justa o clara en el 19, 8% de los pacientes (EAV, 5-6) o fue pobre en el 8, 9% de los pacientes (EAV, 7-10). Luego de tres años de tratamiento continuo, observamos problemas técnicos relacionados con el catéter (dislocación del catéter, obstrucción, doblez, desconexión o ruptura) en 17 de 165 pacientes. Fue muy raro el mal funcionamiento de las bombas (8 de 165 tipos de bombas) y también fue limitado a los tipos más antiguos de bombas. Los efectos colaterales específicos relacionados con las drogas y reversibles en la terapia a largo plazo con las bombas intratecales fueron desarrollados en 32 de 165 pacientes. En nuestra serie, el radio de concentración del fluido cerebroespinal (FCE) /serum principal para la morfina fue de 1/3000, lo cual explica el ritmo bajo que presentan los efectos colaterales sistémicos. Las dificultades de difusión locales en el FCE causan una distribución desigual e irregular de la morfina en el FCE. Por lo tanto, el efecto clínico está influenciado de manera marcada por la posición de la punta del catéter; un hecho que debería ser tenido en cuenta durante el...
- 1 November 2009
- Published by Fundacion Cenit in NeuroTarget
- Vol. 4 (3) , 8-15
Open AccessOpioides por vía intratecal para el tratamiento de los síndromes dolorosos refractarios
For more than 20 years intrathecal opioid application with implantable pumps is an option for selected patients with malignant as well as non-malignant pain. In general, most types of pain should be treatable by opioid medication. However, the associated systemic side-effects such as nausea, vomiting, constipation or the risk of depression of the central nervous system hinder the application of oral or intravenous opioid therapy as a sole, widely applicable treatment. Causes of non-malignant pain that may represent an indication for intrathecal drug-delivery systems include: failed back syndrome, neuropathic pain, axial spinal pain, complex regional pain syndrome, diffuse pain, brachial plexitis, central pain, failed spinal cord stimulation (SCS) therapy, arachnoiditis, poststroke pain, spinal cord injury pain and peripheral neuropathy. Due to the proximity to the receptor sites, the therapeutic effect of intrathecal drug application lasts longer and the rate of systemic side effects is reduced. Before definitive pump implantation, the therapeutic effect of intrathecal opioid therapy is tested with an external pump. If there is no clear and satisfactory effect in this trial application, pump implantation is not indicated. In our patients, with a follow-up exceeding 3 years, the reduction of non-malignant pain (assessed with the Visual Analogue Scale, VAS) was good or excellent (pain decrease >50%) in 71.3% of the patients, fair (VAS 5-6) in 19.8% and poor (VAS 7-10) in 8.9%. After 3 years of continuous treatment, we observed catheter-related technical problems (catheter dislocation, obstruction, kinking, disconnection or rupture) in 17 of 165 patients. Pump malfunctions were very rare (8 of 165 cases) and limited to older pump types. Reversible, specific drug-related side effects of long-term therapy with intrathecal pumps developed in 32 of the 165 patients. In our series, the mean serum/cerebrospinal fluid (CSF) concentration ratio for morphine was 1/3000, which explains the low rate of systemic side effects. Local diffusion difficulties in CSF cause an uneven distribution of morphine in CSF. Therefore the clinical effect is markedly influenced by the position of the catheter tip, a fact that should be kept in mind during catheter implantation. Intrathecal drug application is cost effective and can significantly improve the quality of life in selected patients. An intensive training in this method and awareness of its specific complications is necessary for everyone to participate in the consulting and implanting team. Pumps for chronic intrathecal opioid application should only be implanted in specialized centers. Durante más de veinte años, la aplicación de la terapia con opioides intratecales y con bombas implantables es una opción recurrente para los pacientes seleccionados que presentan dolor maligno o dolor no maligno. Por lo general, la mayor parte de los tipos existentes de dolor deberán ser tratados mediante el uso de medicamentos que contengan opioides. De todos modos, los efectos colaterales adversos sistémicos asociados tales como la náusea, la constipación, el vómito y los riesgos de supresión del sistema nervioso central obstaculizan la aplicación de la terapia intravenosa u oral con opioides como un tratamiento único y de amplia aplicación. Las causas del dolor maligno que pueden representar una indicación de los sistemas intratecales del suministro de drogas incluyen: el dolor neuropático, el síndrome de la cirugía fallida de la espalda, el dolor axial de la columna vertebral, el síndrome de dolor regional complejo, el dolor difuso, la plexitis braquial, el dolor central, la terapia de estimulación fallida de la columna vertebral, la aracnoiditis, el dolor post-stroke, el dolor causado por heridas o lesiones en la columna vertebral y la neuropatía periferal. Debido a la proximidad existente a los sitios receptores, el efecto terapéutico de la aplicación intratecal de las drogas dura más tiempo mientras que el tipo de efectos colaterales adversos sistémicos se reduce. Previamente a realizar el implante definitivo de la bomba, el efecto terapéutico de la terapia con opioides intratecales se prueba con una bomba externa. Si el efecto en esta aplicación de prueba no es ni claro ni satisfactorio, entonces no se indica el implante de la bomba. En nuestros pacientes, mediante un seguimiento que superó los tres años, fue buena la reducción del dolor no maligno (asesorada mediante la aplicación de la Escala Análoga Visual, EAV), fue excelente la reducción del dolor (disminución del dolor del 50%) en el 71, 3 % de los pacientes, fue justa o clara en el 19, 8% de los pacientes (EAV, 5-6) o fue pobre en el 8, 9% de los pacientes (EAV, 7-10). Luego de tres años de tratamiento continuo, observamos problemas técnicos relacionados con el catéter (dislocación del catéter, obstrucción, doblez, desconexión o ruptura) en 17 de 165 pacientes. Fue muy raro el mal funcionamiento de las bombas (8 de 165 tipos de bombas) y también fue limitado a los tipos más antiguos de bombas. Los efectos colaterales específicos relacionados con las drogas y reversibles en la terapia a largo plazo con las bombas intratecales fueron desarrollados en 32 de 165 pacientes. En nuestra serie, el radio de concentración del fluido cerebroespinal (FCE) /serum principal para la morfina fue de 1/3000, lo cual explica el ritmo bajo que presentan los efectos colaterales sistémicos. Las dificultades de difusión locales en el FCE causan una distribución desigual e irregular de la morfina en el FCE. Por lo tanto, el efecto clínico está influenciado de manera marcada por la posición de la punta del catéter; un hecho que debería ser tenido en cuenta durante el...
- 21 August 2009
- Published by Georg Thieme Verlag KG in Central European Neurosurgery
- Vol. 70 (03) , 125-129
The Hour-glass Model of Corpus Callosum Injury
In this retrospective study, the authors analyze the frequency, anatomical distribution and the clinical outcome of 44 patients after severe head injury, with and without lesions of the corpus callosum (CC). 44 patients with severe head injury (GCS3) in all patients with CC injury when compared to patients without CC injury (GOS<4). CC lesions are an important parameter in the assessment of severe brain trauma, hinting at the mechanism of injury as well as the outcome of patients. If a patient does not awake after blunt head injury, MRT scans (including FLAIR sequences) are indicated. A CC lesion alone is not the cause of prolonged coma but indicates a severe diffuse injury resulting in functional deorganization of the brain. The mechanisms of CC injury are discussed and a new pathophysiological model, based on the hour-glass analogy, is presented. Im Rahmen dieser retrospektiven Studie analysieren die Autoren die Frequenz, anatomische Verteilung und die klinischen Langzeitergebnisse bei 44 Patienten nach schwerem Schädel-Hirn-Trauma mit und ohne Verletzung des Corpus callosum. Bei 44 Patienten mit schwerem Schädel-Hirn-Trauma (GCS3) bei allen Patienten mit CC-Verletzung als bei Patienten ohne CC-Verletzung (GOS<4). CC-Verletzungen sind ein wichtiger Parameter bei der Einschätzung eines schweren Schädel-Hirn-Traumas, da sie sowohl Hinweise auf Mechanismen der Entstehung als auch auf das Outcome der Patienten geben. Bei Patienten, die aus durch das CCT nicht hinreichend geklärter Ursache nach stumpfem SHT nicht aufwachen, sollte ein frühes MRT durchgeführt werden. Eine CC-Verletzung ist dabei nicht die Ursache des Komas, weist aber auf eine funktionelle Deorganisation des Gehirns durch diffuse Schädigung hin. Mechanismen der CC-Verletzung werden diskutiert und ein neues pathophysiologisches Modell, basierend auf der „Stundenglass”-Analogie wird vorgestellt.
- 21 August 2009
- Published by Georg Thieme Verlag KG in Central European Neurosurgery
- Vol. 70 (03) , 125-129
The Hour-glass Model of Corpus Callosum Injury
In this retrospective study, the authors analyze the frequency, anatomical distribution and the clinical outcome of 44 patients after severe head injury, with and without lesions of the corpus callosum (CC). 44 patients with severe head injury (GCS3) in all patients with CC injury when compared to patients without CC injury (GOS<4). CC lesions are an important parameter in the assessment of severe brain trauma, hinting at the mechanism of injury as well as the outcome of patients. If a patient does not awake after blunt head injury, MRT scans (including FLAIR sequences) are indicated. A CC lesion alone is not the cause of prolonged coma but indicates a severe diffuse injury resulting in functional deorganization of the brain. The mechanisms of CC injury are discussed and a new pathophysiological model, based on the hour-glass analogy, is presented. Im Rahmen dieser retrospektiven Studie analysieren die Autoren die Frequenz, anatomische Verteilung und die klinischen Langzeitergebnisse bei 44 Patienten nach schwerem Schädel-Hirn-Trauma mit und ohne Verletzung des Corpus callosum. Bei 44 Patienten mit schwerem Schädel-Hirn-Trauma (GCS3) bei allen Patienten mit CC-Verletzung als bei Patienten ohne CC-Verletzung (GOS<4). CC-Verletzungen sind ein wichtiger Parameter bei der Einschätzung eines schweren Schädel-Hirn-Traumas, da sie sowohl Hinweise auf Mechanismen der Entstehung als auch auf das Outcome der Patienten geben. Bei Patienten, die aus durch das CCT nicht hinreichend geklärter Ursache nach stumpfem SHT nicht aufwachen, sollte ein frühes MRT durchgeführt werden. Eine CC-Verletzung ist dabei nicht die Ursache des Komas, weist aber auf eine funktionelle Deorganisation des Gehirns durch diffuse Schädigung hin. Mechanismen der CC-Verletzung werden diskutiert und ein neues pathophysiologisches Modell, basierend auf der „Stundenglass”-Analogie wird vorgestellt.
- 25 May 2009
- Published by Georg Thieme Verlag KG in Central European Neurosurgery
- Vol. 70 (02) , 98-100
Spinal Neurosurgery with the Head-mounted “Varioscope” Microscope
We present a preliminary report on the intra-operative use of a head-mounted microscope (“Varioscope” Leica HM500) in spinal neurosurgery. The Varioscope is a dynamic microscope mounted on a head-set. It weights 297 g and measures 73×120×63 mm (length×width×height). It offers an infinitely variable range of magnification from 3.6× to 7.2×. The working distance ranges from 300 to 600 mm. The field of view varies between 30–144 mm, depending on the selected enlargement factor and the working distance. In addition to the zoom function, the device offers a focus function (automatic or on demand). The optical elements for focus and zoom are located in two separate tubes which are mounted on a middle section containing the mechanical components as well as the receiver unit for the focussing elements. The lenses are adjusted by means of motor-driven push/pull cables. The autofocus works well in larger operative fields and a working distance between 30 and 60 cm. Nevertheless, when used in today's “keyhole” approaches, the autofocus is not helpful when operating in deep structures. Based on the satisfactory results achieved in our series, we can recommend the Varioscope, especially when no stationary microscope is available. The portable device can be packed in a suitcase and can travel with the consultant microsurgeon to different hospitals and distant units. The built-in video camera is ideal for patients, staff, assistant surgeons, and student education with real-time video monitoring of procedures from the microsurgeon's perspective. For daily microsurgery, we felt more comfortable with fixed, stationary operating microscopes. Wir berichten über erste klinische Erfahrungen bei der Verwendung eines tragbaren Operationsmikroskops („Varioscope” Leica HM500) in der spinalen Neurochirurgie. Das Varioscope ist ein dynamisches Mikroskop, das wie ein Helm auf dem Kopf tragbar ist. Das Gewicht beträgt 297 g, die Größe des Geräts beträgt 73×120×63 mm (Länge×Breite×Höhe). Eine stufenlose Zoomfunktion erlaubt Vergrößerungen zwischen 3,6× und 7,2×. Der Arbeitsabstand liegt zwischen 30 und 60 cm. Die Größe des Gesichtsfeldes beträgt 30–144 mm, abhängig von der gewählten Vergrößerungsstufe und dem Arbeitsabstand. Das Gerät ist mit einer automatischen und manuellen Fokusfunktion ausgestattet, die Messung der Entfernung erfolgt automatisch mittels eingebauter Ultraschallsensoren. Die optischen Elemente für Fokus und Zoom sind in zwei separate Röhren eingebaut, die in der Mitte des Mikroskops zwischen den Linsenkanälen angebracht sind. Der Autofokus arbeitet problemlos mit größeren Operationsfeldern und einem Arbeitsabstand zwischen 30 und 60 cm. Probleme mit dem Autofokus traten bei minimal invasiven „Schlüsselloch”- Zugängen auf; Bei der mikrochirurgischen Präparation an der Dura z. B. wurde der Fokus meist auf „manuell” gestellt um ein „Springen” des Autofokus zu vermeiden. Auf Grund unserer Erfahrungen können wir das Varioscope für Situationen in denen kein feststehendes Operationsmikroskop verfügbar ist, empfehlen. Das tragbare Gerät kann in einem Koffer problemlos transportiert werden und kann mit dem konsultierenden Mikrochirurgen in die verschiedenen ggf. entlegenen Krankenhäuser reisen. Die eingebaute Videokamera erlaubt Dokumentation, Qualitätskontrolle, chirurgische Ausbildung und Lehre aus der Sicht des Mikrochirurgen. Für die tägliche Arbeit in einem spezialisierten Krankenhaus kann es ein stationäres Operationsmikroskop aber derzeit noch nicht ersetzen.
- 25 May 2009
- Published by Georg Thieme Verlag KG in Central European Neurosurgery
- Vol. 70 (02) , 98-100
Spinal Neurosurgery with the Head-mounted “Varioscope” Microscope
We present a preliminary report on the intra-operative use of a head-mounted microscope (“Varioscope” Leica HM500) in spinal neurosurgery. The Varioscope is a dynamic microscope mounted on a head-set. It weights 297 g and measures 73×120×63 mm (length×width×height). It offers an infinitely variable range of magnification from 3.6× to 7.2×. The working distance ranges from 300 to 600 mm. The field of view varies between 30–144 mm, depending on the selected enlargement factor and the working distance. In addition to the zoom function, the device offers a focus function (automatic or on demand). The optical elements for focus and zoom are located in two separate tubes which are mounted on a middle section containing the mechanical components as well as the receiver unit for the focussing elements. The lenses are adjusted by means of motor-driven push/pull cables. The autofocus works well in larger operative fields and a working distance between 30 and 60 cm. Nevertheless, when used in today's “keyhole” approaches, the autofocus is not helpful when operating in deep structures. Based on the satisfactory results achieved in our series, we can recommend the Varioscope, especially when no stationary microscope is available. The portable device can be packed in a suitcase and can travel with the consultant microsurgeon to different hospitals and distant units. The built-in video camera is ideal for patients, staff, assistant surgeons, and student education with real-time video monitoring of procedures from the microsurgeon's perspective. For daily microsurgery, we felt more comfortable with fixed, stationary operating microscopes. Wir berichten über erste klinische Erfahrungen bei der Verwendung eines tragbaren Operationsmikroskops („Varioscope” Leica HM500) in der spinalen Neurochirurgie. Das Varioscope ist ein dynamisches Mikroskop, das wie ein Helm auf dem Kopf tragbar ist. Das Gewicht beträgt 297 g, die Größe des Geräts beträgt 73×120×63 mm (Länge×Breite×Höhe). Eine stufenlose Zoomfunktion erlaubt Vergrößerungen zwischen 3,6× und 7,2×. Der Arbeitsabstand liegt zwischen 30 und 60 cm. Die Größe des Gesichtsfeldes beträgt 30–144 mm, abhängig von der gewählten Vergrößerungsstufe und dem Arbeitsabstand. Das Gerät ist mit einer automatischen und manuellen Fokusfunktion ausgestattet, die Messung der Entfernung erfolgt automatisch mittels eingebauter Ultraschallsensoren. Die optischen Elemente für Fokus und Zoom sind in zwei separate Röhren eingebaut, die in der Mitte des Mikroskops zwischen den Linsenkanälen angebracht sind. Der Autofokus arbeitet problemlos mit größeren Operationsfeldern und einem Arbeitsabstand zwischen 30 und 60 cm. Probleme mit dem Autofokus traten bei minimal invasiven „Schlüsselloch”- Zugängen auf; Bei der mikrochirurgischen Präparation an der Dura z. B. wurde der Fokus meist auf „manuell” gestellt um ein „Springen” des Autofokus zu vermeiden. Auf Grund unserer Erfahrungen können wir das Varioscope für Situationen in denen kein feststehendes Operationsmikroskop verfügbar ist, empfehlen. Das tragbare Gerät kann in einem Koffer problemlos transportiert werden und kann mit dem konsultierenden Mikrochirurgen in die verschiedenen ggf. entlegenen Krankenhäuser reisen. Die eingebaute Videokamera erlaubt Dokumentation, Qualitätskontrolle, chirurgische Ausbildung und Lehre aus der Sicht des Mikrochirurgen. Für die tägliche Arbeit in einem spezialisierten Krankenhaus kann es ein stationäres Operationsmikroskop aber derzeit noch nicht ersetzen.
- 22 April 2009
- Published by Springer Nature in European Spine Journal
- Vol. 18 (6) , 823-829
Two-year results of interspinous spacer (X-Stop) implantation in 175 patients with neurologic intermittent claudication due to lumbar spinal stenosis
The clinical outcome of patients with symptomatic lumbar spinal stenosis (LSS) was assessed during a follow-up period of 2 years after X-Stop implantation. The X-Stop is the most commonly used interspinous distraction device in patients with neurogenic intermittent claudication due to LSS. Between 2003 and 2007, more than 1,000 patients were examined in our centre with symptoms of intermittent claudication due to spinal stenosis. Between February 2003 and June 2007, in 175 of these patients an X-Stop device was implanted in one or two levels. Patients were clinically evaluated regularly during a follow-up period of up to 4 years using the VAS (leg pain) score and the Oswestry disability index. The mean VAS (leg pain) score in these 175 patients was reduced from 61.2% preoperatively to 39.0% at the first clincal follow-up examination at 6 weeks postoperatively. The mean VAS score at 24 months postoperatively was 39.0%. Oswestry score was 32.6% preoperatively, 22.7% at 6 weeks, and 20.3% at 24 months postoperatively on average. In eight out of the implanted 175 patients, the X-Stop had to be removed and a microsurgical decompression had to be performed because of unsatisfactory effect of the interspinous distraction device. Our single-centre results indicate not only a satisfactory short-term, but also a good long-term effect during a follow-up period of 2 years. Functional MRI examinations provide helpful, positional-dependent preoperative information. More than any radiological feature, the typical clinical picture of positional-dependent claudication with a relief of symptoms during flexion is the most important factor for appropriate patient selection. The interspinous device does not replace microsurgical decompression in patients with massive stenosis and continuous claudication, but offers a save, effective and less invasive alternative in selected patients with spinal stenosis. Concerning the operative technique, a minimally invasive implantation with preservation of the interspinous ligament is appropriate. Functional (upright-) MRI examinations were able to demonstrate the positional-dependent stenosis. If available, fMRI represents the most helpful radiologic examination in assessing the outcome of interspinous spacer implantation.
- 22 April 2009
- Published by Springer Nature in European Spine Journal
- Vol. 18 (6) , 823-829
Two-year results of interspinous spacer (X-Stop) implantation in 175 patients with neurologic intermittent claudication due to lumbar spinal stenosis
The clinical outcome of patients with symptomatic lumbar spinal stenosis (LSS) was assessed during a follow-up period of 2 years after X-Stop implantation. The X-Stop is the most commonly used interspinous distraction device in patients with neurogenic intermittent claudication due to LSS. Between 2003 and 2007, more than 1,000 patients were examined in our centre with symptoms of intermittent claudication due to spinal stenosis. Between February 2003 and June 2007, in 175 of these patients an X-Stop device was implanted in one or two levels. Patients were clinically evaluated regularly during a follow-up period of up to 4 years using the VAS (leg pain) score and the Oswestry disability index. The mean VAS (leg pain) score in these 175 patients was reduced from 61.2% preoperatively to 39.0% at the first clincal follow-up examination at 6 weeks postoperatively. The mean VAS score at 24 months postoperatively was 39.0%. Oswestry score was 32.6% preoperatively, 22.7% at 6 weeks, and 20.3% at 24 months postoperatively on average. In eight out of the implanted 175 patients, the X-Stop had to be removed and a microsurgical decompression had to be performed because of unsatisfactory effect of the interspinous distraction device. Our single-centre results indicate not only a satisfactory short-term, but also a good long-term effect during a follow-up period of 2 years. Functional MRI examinations provide helpful, positional-dependent preoperative information. More than any radiological feature, the typical clinical picture of positional-dependent claudication with a relief of symptoms during flexion is the most important factor for appropriate patient selection. The interspinous device does not replace microsurgical decompression in patients with massive stenosis and continuous claudication, but offers a save, effective and less invasive alternative in selected patients with spinal stenosis. Concerning the operative technique, a minimally invasive implantation with preservation of the interspinous ligament is appropriate. Functional (upright-) MRI examinations were able to demonstrate the positional-dependent stenosis. If available, fMRI represents the most helpful radiologic examination in assessing the outcome of interspinous spacer implantation.
- 1 April 2009
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 16 (3) , 159-161
Multiple cranial gunshot injuries without skull penetration
- 1 April 2009
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 16 (3) , 159-161
Multiple cranial gunshot injuries without skull penetration
- 1 January 2007
- Published by Springer Nature
- Vol. 97, 65-70
Neurosurgical pain therapy with epidural spinal cord stimulation (SCS)
Neurosurgical therapy for intractable pain with epidural implantable electrodes has become a widely used and efficient alternative when conservative or less invasive therapies are no longer effective. A complete interdisciplinary work-up is required before considering a patient as a candidate for a spinal cord stimulation (SCS) device. In more than 1300 patients we implanted an SCS device in our clinic; more than 52% reported a significant (>50%) long-term improvement for more than 3 years and a significant reduction in their analgesic drugs. Although placement of the electrode and implantation of the stimulator are technically easy to perform, they do carry a risk of potentially debilitating complications such as meningitis or component migration. Hence, SCS therapy should only be performed in specialized centers. In peripheral vascular disease (PVD) and angina, the initial results are very promising, but the long-term efficacy has to be proven by multicenter studies.
- 1 January 2007
- Published by Springer Nature
- Vol. 97, 65-70
Neurosurgical pain therapy with epidural spinal cord stimulation (SCS)
Neurosurgical therapy for intractable pain with epidural implantable electrodes has become a widely used and efficient alternative when conservative or less invasive therapies are no longer effective. A complete interdisciplinary work-up is required before considering a patient as a candidate for a spinal cord stimulation (SCS) device. In more than 1300 patients we implanted an SCS device in our clinic; more than 52% reported a significant (>50%) long-term improvement for more than 3 years and a significant reduction in their analgesic drugs. Although placement of the electrode and implantation of the stimulator are technically easy to perform, they do carry a risk of potentially debilitating complications such as meningitis or component migration. Hence, SCS therapy should only be performed in specialized centers. In peripheral vascular disease (PVD) and angina, the initial results are very promising, but the long-term efficacy has to be proven by multicenter studies.
- 1 January 2007
- Published by Springer Nature
- Vol. 97, 181-184
Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study
Since 1986, more than 300 patients received an intrathecal baclofen (ITB) pump for the treatment of severe spasticity. Chronic ITB administration is a safe and effective method, which significantly decreases pathologically exaggerated muscle tone and improves the quality of life in most patients. This therapy is indicated in severe spasticity of cerebral or spinal origin that is unresponsive to oral antispastic medications. It is also useful in patients who may experience intolerable side effects when they receive orally effective baclofen doses. The therapeutic dose required to treat spasticity of cerebral origin is about three times higher than in spasticity of spinal origin. In carefully selected patients who suffer from spasticity, pump implantation is a cost-effective treatment which improves their quality of life. In our series with a follow-up period of 10 years, the ITB dose remained constant and no development of tolerance was observed in most patients. Destructive procedures such as myelotomy are no longer performed in our department in order to treat spasticity.
- 1 January 2007
- Published by Springer Nature
- Vol. 97, 181-184
Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study
Since 1986, more than 300 patients received an intrathecal baclofen (ITB) pump for the treatment of severe spasticity. Chronic ITB administration is a safe and effective method, which significantly decreases pathologically exaggerated muscle tone and improves the quality of life in most patients. This therapy is indicated in severe spasticity of cerebral or spinal origin that is unresponsive to oral antispastic medications. It is also useful in patients who may experience intolerable side effects when they receive orally effective baclofen doses. The therapeutic dose required to treat spasticity of cerebral origin is about three times higher than in spasticity of spinal origin. In carefully selected patients who suffer from spasticity, pump implantation is a cost-effective treatment which improves their quality of life. In our series with a follow-up period of 10 years, the ITB dose remained constant and no development of tolerance was observed in most patients. Destructive procedures such as myelotomy are no longer performed in our department in order to treat spasticity.
- 31 December 2006
- Published by Springer Nature
- Vol. 97, 443-449
Twenty-five years of auditory brainstem implants: perspectives
The auditory brainstem implant (ABI) provides auditory sensations, recognition of environmental sounds and aid in spoken communication in more than 300 patients worldwide. It is no more a device under investigation but it is widely accepted for the treatment of patients who have lost hearing due to bilateral tumors of the vestibulocochlear nerve. Most of these patients are completely deaf when the implant is switched off. In contrast to the cochlear implants (CI), only few of the implanted patients achieve open-set speech recognition without the help of visual cues. In the last few years, patients with lesions other than tumors have also been implanted. Auditory perceptual performance in patients who are deaf due to trauma, cochlea aplasia or other non-tumor lesions of the cochlea or the vestibulocochlear nerve turned out to be much better than in NF2 tumor patients. Until recently, the target region for ABI implantation has been the ventral cochlear nucleus (CN). The electrodes are implanted via the translabyrinthine or retrosigmoid approach. Currently, new targets along the central auditory pathways and new, minimally invasive techniques for implantation are under investigation. These techniques may further improve auditory perceptual performance in ABI patients and provide hearing to a variety of types of central deafness.
- 31 December 2006
- Published by Springer Nature
- Vol. 97, 443-449
Twenty-five years of auditory brainstem implants: perspectives
The auditory brainstem implant (ABI) provides auditory sensations, recognition of environmental sounds and aid in spoken communication in more than 300 patients worldwide. It is no more a device under investigation but it is widely accepted for the treatment of patients who have lost hearing due to bilateral tumors of the vestibulocochlear nerve. Most of these patients are completely deaf when the implant is switched off. In contrast to the cochlear implants (CI), only few of the implanted patients achieve open-set speech recognition without the help of visual cues. In the last few years, patients with lesions other than tumors have also been implanted. Auditory perceptual performance in patients who are deaf due to trauma, cochlea aplasia or other non-tumor lesions of the cochlea or the vestibulocochlear nerve turned out to be much better than in NF2 tumor patients. Until recently, the target region for ABI implantation has been the ventral cochlear nucleus (CN). The electrodes are implanted via the translabyrinthine or retrosigmoid approach. Currently, new targets along the central auditory pathways and new, minimally invasive techniques for implantation are under investigation. These techniques may further improve auditory perceptual performance in ABI patients and provide hearing to a variety of types of central deafness.
- 31 December 2006
- Published by Springer Nature
- Vol. 97, 43-48
Intrathecal opioids for intractable pain syndromes
For more than 20 years intrathecal opioid application with implantable pumps is an option for selected patients with malignant as well as non-malignant pain. In general, most types of pain should be treatable by opioid medication. However, the associated systemic side-effects such as nausea, vomiting, constipation or the risk of suppression of the central nervous system hinder the application of oral or intravenous opioid therapy as a sole, widely applicable treatment. Causes of non-malignant pain that may represent an indication for intrathecal drug-delivery systems include: failed back syndrome, neuropathic pain, axial spinal pain, complex regional pain syndrome, diffuse pain, brachial plexitis, central pain, failed spinal cord stimulation (SCS) therapy, arachnoiditis, poststroke pain, spinal cord injury pain and peripheral neuropathy. Due to the proximity to the receptor sites, the therapeutic effect of intrathecal drug application lasts longer and the rate of systemic side effects is reduced. Before definitive pump implantation, the therapeutic effect of intrathecal opioid therapy is tested with an external pump. If there is no clear and satisfactory effect in this trial application, pump implantation is not indicated. In our patients, with a follow-up exceeding 3 years, the reduction of non-malignant pain (assessed with the Visual Analogue Scale, VAS) was good or excellent (pain decrease >50%) in 71.3% of the patients, fair (VAS 5–6) in 19.8% and poor (VAS 7-10) in 8.9%. After 3 years of continuous treatment, we observed catheter-related technical problems (catheter dislocation, obstruction, kinking, disconnection or rupture) in 17 of 165 patients. Pump malfunctions were very rare (8 of 165 cases) and limited to older pump types. Reversible, specific drug-related side effects of long-term therapy with intrathecal pumps developed in 32 of the 165 patients. In our series, the mean serum/cerebrospinal fluid (CSF) concentration ratio for morphine was 1/3000, which explains the low rate of systemic side effects. Local diffusion difficulties in CSF cause an uneven distribution of morphine in CSF. Therefore the clinical effect is markedly influenced by the position of the catheter tip, a fact that should be kept in mind during catheter implantation. Intrathecal drug application is cost effective and can significantly improve the quality of life in selected patients. An intensive training in this method and awareness of its specific complications is necessary for everyone to participate in the consulting and implanting team. Pumps for chronic intrathecal opioid application should only be implanted in specialized centers.
- 31 December 2006
- Published by Springer Nature
- Vol. 97, 43-48
Intrathecal opioids for intractable pain syndromes
For more than 20 years intrathecal opioid application with implantable pumps is an option for selected patients with malignant as well as non-malignant pain. In general, most types of pain should be treatable by opioid medication. However, the associated systemic side-effects such as nausea, vomiting, constipation or the risk of suppression of the central nervous system hinder the application of oral or intravenous opioid therapy as a sole, widely applicable treatment. Causes of non-malignant pain that may represent an indication for intrathecal drug-delivery systems include: failed back syndrome, neuropathic pain, axial spinal pain, complex regional pain syndrome, diffuse pain, brachial plexitis, central pain, failed spinal cord stimulation (SCS) therapy, arachnoiditis, poststroke pain, spinal cord injury pain and peripheral neuropathy. Due to the proximity to the receptor sites, the therapeutic effect of intrathecal drug application lasts longer and the rate of systemic side effects is reduced. Before definitive pump implantation, the therapeutic effect of intrathecal opioid therapy is tested with an external pump. If there is no clear and satisfactory effect in this trial application, pump implantation is not indicated. In our patients, with a follow-up exceeding 3 years, the reduction of non-malignant pain (assessed with the Visual Analogue Scale, VAS) was good or excellent (pain decrease >50%) in 71.3% of the patients, fair (VAS 5–6) in 19.8% and poor (VAS 7-10) in 8.9%. After 3 years of continuous treatment, we observed catheter-related technical problems (catheter dislocation, obstruction, kinking, disconnection or rupture) in 17 of 165 patients. Pump malfunctions were very rare (8 of 165 cases) and limited to older pump types. Reversible, specific drug-related side effects of long-term therapy with intrathecal pumps developed in 32 of the 165 patients. In our series, the mean serum/cerebrospinal fluid (CSF) concentration ratio for morphine was 1/3000, which explains the low rate of systemic side effects. Local diffusion difficulties in CSF cause an uneven distribution of morphine in CSF. Therefore the clinical effect is markedly influenced by the position of the catheter tip, a fact that should be kept in mind during catheter implantation. Intrathecal drug application is cost effective and can significantly improve the quality of life in selected patients. An intensive training in this method and awareness of its specific complications is necessary for everyone to participate in the consulting and implanting team. Pumps for chronic intrathecal opioid application should only be implanted in specialized centers.
- 1 January 2004
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 100 (1) , 16-23
The multichannel auditory brainstem implant: how many electrodes make sense?
Object. Development of multichannel auditory brainstem implant (ABI) systems has been based in part on the assumption that audiological outcome can be optimized by increasing the number of available electrodes. In this paper the authors critically analyze this assumption on the basis of a retrospective clinical study performed using the Nucleus 22 ABI surface electrode array. Methods. The perceptual performances of 61 patients with neurofibromatosis Type 2 were tested approximately 6 weeks after an eight-electrode ABI had been implanted. Of eight implanted electrodes 5.57 ± 2.57 (mean ± standard deviation [SD] provided auditory sensations when stimulated. Electrodes were deactivated when stimulation resulted in significant nonauditory side effects or no auditory sensation at all, and also when they failed to provide distinctive pitch sensations. The mean (± SD) scores for patients with ABIs were the following: sound-only consonant recognition, 20.4 ± 14.3 (range 0–65%); vowel recognition, 28.8 ± 18% (range 0–67%); Monosyllable Trochee Spondee (MTS) word recognition 41.1 ± 25.3% (range 0–100%); and sentence recognition, 5.3 ± 11.4% (range 0–64%). Performance in patients in whom between one and three electrodes provided auditory sensation was significantly poorer than that in patients with between four and eight functional electrodes in the vowel, MTS word, and City University of New York (CUNY) sentence recognition tests. The correlation between performance and electrode number did not reach the 0.05 level of significance with respect to the sound effect, consonant, and MTS stress-pattern recognition tests, probably because a satisfactory performance in these tests can be obtained only with temporal cues, that is, without any information about the frequency of the sounds. In the MTS word and the CUNY sentence recognition tests, performance was optimal in the patients with eight functional electrodes. Although all top performers had more than three functional auditory electrodes, no further improvement (asymptotic performance) was seen in those with five or more active electrodes in the consonant, vowel, and sound effect recognition tests. Conclusions. A minimum of three spectral channels, programmed in the appropriate individual tonotopic order seem to be required for satisfactory speech recognition in most patients with ABI. Due to the limited access to the tonotopic frequency gradient of the cochlear nucleus with surface stimulation, patients with ABI do not receive a wide range of spectral cues (frequency information) with multielectrode (> 5) surface arrays.
- 1 January 2004
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 100 (1) , 16-23
The multichannel auditory brainstem implant: how many electrodes make sense?
Object. Development of multichannel auditory brainstem implant (ABI) systems has been based in part on the assumption that audiological outcome can be optimized by increasing the number of available electrodes. In this paper the authors critically analyze this assumption on the basis of a retrospective clinical study performed using the Nucleus 22 ABI surface electrode array. Methods. The perceptual performances of 61 patients with neurofibromatosis Type 2 were tested approximately 6 weeks after an eight-electrode ABI had been implanted. Of eight implanted electrodes 5.57 ± 2.57 (mean ± standard deviation [SD] provided auditory sensations when stimulated. Electrodes were deactivated when stimulation resulted in significant nonauditory side effects or no auditory sensation at all, and also when they failed to provide distinctive pitch sensations. The mean (± SD) scores for patients with ABIs were the following: sound-only consonant recognition, 20.4 ± 14.3 (range 0–65%); vowel recognition, 28.8 ± 18% (range 0–67%); Monosyllable Trochee Spondee (MTS) word recognition 41.1 ± 25.3% (range 0–100%); and sentence recognition, 5.3 ± 11.4% (range 0–64%). Performance in patients in whom between one and three electrodes provided auditory sensation was significantly poorer than that in patients with between four and eight functional electrodes in the vowel, MTS word, and City University of New York (CUNY) sentence recognition tests. The correlation between performance and electrode number did not reach the 0.05 level of significance with respect to the sound effect, consonant, and MTS stress-pattern recognition tests, probably because a satisfactory performance in these tests can be obtained only with temporal cues, that is, without any information about the frequency of the sounds. In the MTS word and the CUNY sentence recognition tests, performance was optimal in the patients with eight functional electrodes. Although all top performers had more than three functional auditory electrodes, no further improvement (asymptotic performance) was seen in those with five or more active electrodes in the consonant, vowel, and sound effect recognition tests. Conclusions. A minimum of three spectral channels, programmed in the appropriate individual tonotopic order seem to be required for satisfactory speech recognition in most patients with ABI. Due to the limited access to the tonotopic frequency gradient of the cochlear nucleus with surface stimulation, patients with ABI do not receive a wide range of spectral cues (frequency information) with multielectrode (> 5) surface arrays.